GlassScriptPhysician profile
Heather T Lechnowsky
NPI 1568562064
$1,295.42
in general payments reported to CMS, 2019-2025
21 companies · $823 in 2025
The $823 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.23 · 2023: $45.93 · 2024: $413 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,263 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,262.57 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $211.32 | 2024-2025 | |
| Amgen INC. | $180.51 | 2024-2025 | Tavneos, Krystexxa, Aranesp |
| Fresenius USA Marketing, INC. | $98.27 | 2024-2025 | Velphoro, Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.78 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $86.14 | 2024-2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $74.02 | 2022-2025 | Farxiga |
| Travere Therapeutics, INC. | $71.37 | 2024-2025 | |
| Glaxosmithkline, LLC. | $69.47 | 2024-2025 | Benlysta, Arexvy, Shingrix |
| Ani Pharmaceuticals, INC. | $64.08 | 2025 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $59.90 | 2023-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $50.11 | 2023-2025 | |
| Lilly USA, LLC | $46.31 | 2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $34.21 | 2024-2025 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $29.82 | 2024 | Jynarque |
| Calliditas Therapeutics US INC. | $22.28 | 2025 | Tarpeyo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $22.14 | 2025 | Injectafer |
| Nxstage Medical, INC. | $19.85 | 2024 | |
| Mozarc Medical US LLC | $17.25 | 2024 | Palindrome |
| Lexicon Pharmaceuticals, INC. | $17.14 | 2024 | |
| Xeris Pharmaceuticals, INC. | $15.28 | 2025 | Keveyis |
| Scpharmaceuticals INC. | $15.17 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Lechnowsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.